Front Pediatr

. 2022 Jul 1;10:911588.

 doi: 10.3389/fped.2022.911588. eCollection 2022. https://pubmed.ncbi.nlm.nih.gov/35844758/

Use of Prostaglandin E1 in the Management of Congenital Diaphragmatic Hernia-A Review

Srirupa Hari Gopal ¹, Neil Patel ², Caraciolo J Fernandes ¹

Affiliations expand

• PMID: 35844758
• PMCID: PMC9283565
• DOI: 10.3389/fped.2022.911588

Free PMC article

Abstract

Congenital diaphragmatic hernia (CDH) is a rare congenital anomaly, whose presentation is complicated by pulmonary hypertension (PH), pulmonary hypoplasia, and myocardial dysfunction, each of which have significant impact on short-term clinical management and long-term outcomes. Despite many advances in therapy and surgical technique, optimal CDH management remains a topic of debate, due to the variable presentation, complex pathophysiology, and continued impact on morbidity and mortality. One of the more recent management strategies is the use of prostaglandin E1 (PGE1) infusion in the management of PH associated with CDH. PGE1 is widely used in the NICU in critical congenital cardiac disease to maintain ductal patency and facilitate pulmonary and systemic blood flow. In a related paradigm, PGE1 infusion has been used in situations of supra-systemic right ventricular pressures, including CDH, with the therapeutic intent to maintain ductal patency as a “pressure relief valve” to reduce the effective afterload on the right ventricle (RV), optimize cardiac function and support pulmonary and systemic blood flow. This paper reviews the current evidence for use of PGE1 in the CDH population and the opportunities for future investigations.

Keywords: Congenital Diaphragmatic Hernia (CDH); Patent Ductus Arteriosus (PDA); prostagladin E1; pulmonary hypertension; ventricular dysfunction.

Copyright © 2022 Hari Gopal, Patel and Fernandes.